Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

AstraZeneca plc. (8/4/09). "Press Release: AstraZeneca and Astellas Enter Agreement for Co-promotion of Symbicort Turbuholer in Japan".

Organisations Organisation AstraZeneca (Group)
  Organisation 2 Astellas Pharma Inc. (TSE: 4503)
  Group Astellas (Group)
Products Product Symbicort®
  Product 2 budesonide (INN)
Person Person Angelici, Bruno (AstraZeneca 200812 Executive VP Intern Sales + Marketing)
     


AstraZeneca and Astellas Pharma Inc. today announced an agreement for the co-promotion of AstraZeneca's Symbicort Turbuhaler (budesonide/ formoterol, a dry powder inhaler), for the treatment of bronchial asthma in Japan.

Under the agreement, AstraZeneca and Astellas will co-promote Symbicort Turbuhaler and Astellas will be responsible for distribution of the product. Astellas will make an upfront payment of ¥3.0 billion (about US$31.5 million at current exchange rates) to AstraZeneca in addition to milestone payments of up to ¥5.5 billion (about US$57.7 million at current exchange rates) depending on the achievement of certain sales and approval of an additional indication by the Japanese authority.

Symbicort Turbuhaler is not currently available in Japan. AstraZeneca submitted a new drug application (NDA) in Japan in May, 2007. The outcome of this submission is expected in the fourth quarter of 2009. Development is also under way for an indication to treat chronic obstructive pulmonary disease (COPD).

"We are extremely pleased to have formed this new collaboration with Astellas. Astellas has been a long time partner of AstraZeneca and has one of the strongest sales and marketing organisations in Japan," said Bruno Angelici, Executive Vice President for International Sales and Marketing. "Partnering with Astellas will ensure that we successfully launch and maximise the potential of Symbicort Turbuhaler for the roughly five million people in Japan living with asthma."

-ENDS-

NOTES TO EDITORS:

About Symbicort

Symbicort Turbuhaler is a twice-daily inhaled treatment for asthma. It combines an inhaled corticosteroid, budesonide, and a rapid and long-acting Beta 2 agonist, formoterol, in a single inhalation device.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas has approximately 14,200 employees worldwide. The organization is committed to becoming a global category leader by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information on Astellas Pharma Inc., please visit our website at http://www.astellas.com/en/.

CONTACTS:
Media Enquiries:
Neil McCrae +44 207 304 5045 (24 hours) Chris Sampson +44 20 7304 5130 (24 hours)
Sarah Lindgreen +44 20 7304 5033 (24 hours)
Investor Enquiries UK: Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Karl Hard +44 207 304 5322 mob: +44 7789 654364
Investor Enquiries US: Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043

4 August 2009

# # #

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top